Cristal Therapeutics is a clinical-stage business with a pipeline of proprietary drug candidates based on its nanoparticle technology platform, CriPec®, for enhancing and enabling the targeted delivery of injectables in various therapeutic areas including oncology.
Cristal Therapeutics is a clinical-stage pharmaceutical company developing targeted nanomedicines with superior therapeutic profiles for the treatment of cancer and other diseases. Its product candidates, based on the proprietary polymeric nanoparticle technoloy, CriPec®, are rationally designed to target specific tissue, cells and intracellular components, and to have a defined duration at disease sites.
It’s lead candidate, a CriPec® formulation of docetaxel, is in Phase II clinical trials for the treatment of solid tumours.
Cristal Therapeutics was founded in 2011 as a spin-off from Utrecht University, The Netherlands. It is privately held, having raised more than €30 million from private investors.